Highlights Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
1.33 ^USD	+1.53%		0.00%	-31.09%

May. 14	Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	Apr. 23	MT
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	Apr. 23	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 15	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	Feb. 06	CI
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	Dec. 12	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	23-09-27	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema	23-06-21	CI
Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Unity Biotechnology, Inc. Announces Positive 48-Week Results from Phase 2 Bold Study of UBX1325 in Patients with Diabetic Macular Edema	23-04-24	CI
Unity Biotechnology, Inc. Announces Results from Part A of the Phase 2 Envision Study	23-03-27	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema	22-11-01	CI
Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration	22-09-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Highlights

Filters